Immune checkpoint blockers (ICBs) have failed in all Phase III glioblastoma trials. Here, we found that ICBs induce cerebral edema in some patients and mice with glioblastoma. Through single-cell RNA

NIAID Data Ecosystem60

Additional file 7 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

胶质母细胞瘤免疫治疗

表观遗传药物机制

Additional file 7: Table S1: Upstream regulators by guadecitabine in all tumor types; Table S2: Enrichment analysis of Upstream regulators up-regulated in GBM vs MM-BM; Table S3: Enrichment analysis o

NIAID Data Ecosystem40

cGAS-agonistic Spherical Nucleic Acids reprogram the glioblastoma immune microenvironment and promote anti-tumor immunity

胶质母细胞瘤免疫治疗

核酸药物递送

Intratumorally delivered STING-agonistic cyclic dinucleotides (CDN) exhibit therapeutic benefit in preclinical glioblastoma (GBM) models, but inadequate bioavailability limits CDN therapy to invasive

NIAID Data Ecosystem20

Additional file 4 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

资源简介：

Additional file 4 of Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

资源简介：

相关数据集